Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$360.4m

Entrada Therapeutics Valuation

Is TRDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TRDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TRDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRDA?

Key metric: As TRDA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TRDA. This is calculated by dividing TRDA's market cap by their current revenue.
What is TRDA's PS Ratio?
PS Ratio5.9x
SalesUS$61.52m
Market CapUS$360.41m

Price to Sales Ratio vs Peers

How does TRDA's PS Ratio compare to its peers?

The above table shows the PS ratio for TRDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.5x
TLSI TriSalus Life Sciences
7.6x27.49%US$304.8m
XOMA XOMA Royalty
7.4x28.15%US$346.6m
ACIU AC Immune
60.3x45.46%US$332.4m
FENC Fennec Pharmaceuticals
6.8x26.33%US$262.3m
TRDA Entrada Therapeutics
5.9x-32.10%US$360.4m

Price-To-Sales vs Peers: TRDA is good value based on its Price-To-Sales Ratio (5.9x) compared to the peer average (20.5x).

Price to Sales Ratio vs Industry

How does TRDA's PS Ratio compare vs other companies in the US Biotechs Industry?

121 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.6x-1.44%US$26.09b
BMRN BioMarin Pharmaceutical
3.7x5.77%US$11.42b
PTCT PTC Therapeutics
3.5x1.28%US$6.16b
ALKS Alkermes
3.1x8.02%US$4.67b
TRDA 5.9xIndustry Avg. 11.7xNo. of Companies121PS01632486480+
121 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TRDA is good value based on its Price-To-Sales Ratio (5.9x) compared to the US Biotechs industry average (11.7x).

Price to Sales Ratio vs Fair Ratio

What is TRDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.9x
Fair PS Ratio0.04x

Price-To-Sales vs Fair Ratio: TRDA is expensive based on its Price-To-Sales Ratio (5.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TRDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.05
US$16.50
+64.18%
21.21%US$20.00US$13.00n/a2
Dec ’26US$9.91
US$16.50
+66.50%
21.21%US$20.00US$13.00n/a2
Nov ’26US$6.95
US$18.50
+166.19%
8.11%US$20.00US$17.00n/a2
Oct ’26US$5.88
US$18.50
+214.63%
8.11%US$20.00US$17.00n/a2
Sep ’26US$5.47
US$18.50
+238.21%
8.11%US$20.00US$17.00n/a2
Aug ’26US$5.80
US$20.50
+253.45%
2.44%US$21.00US$20.00n/a2
Jul ’26US$7.11
US$20.50
+188.33%
2.44%US$21.00US$20.00n/a2
Jun ’26US$7.60
US$20.50
+169.74%
2.44%US$21.00US$20.00n/a2
May ’26US$9.05
US$24.33
+168.88%
17.22%US$30.00US$20.00n/a3
Apr ’26US$8.76
US$25.43
+190.27%
16.10%US$30.00US$20.00n/a4
Mar ’26US$11.94
US$25.43
+112.96%
16.10%US$30.00US$20.00n/a4
Feb ’26US$13.44
US$26.43
+96.63%
14.11%US$29.00US$20.00n/a4
Jan ’26US$17.29
US$26.43
+52.85%
14.11%US$29.00US$20.00US$10.284
Dec ’25US$19.89
US$25.57
+28.56%
15.44%US$28.71US$20.00US$9.913
Nov ’25US$17.60
US$23.90
+35.81%
18.58%US$28.71US$18.00US$6.953
Oct ’25US$16.00
US$23.90
+49.40%
18.58%US$28.71US$18.00US$5.883
Sep ’25US$17.70
US$23.90
+35.05%
18.58%US$28.71US$18.00US$5.473
Aug ’25US$15.96
US$23.20
+45.34%
16.09%US$26.59US$18.00US$5.803
Jul ’25US$14.32
US$23.20
+61.99%
16.09%US$26.59US$18.00US$7.113
Jun ’25US$15.47
US$23.86
+54.26%
11.77%US$26.59US$20.00US$7.603
May ’25US$13.25
US$21.00
+58.49%
4.76%US$22.00US$20.00US$9.052
Apr ’25US$13.76
US$21.00
+52.62%
4.76%US$22.00US$20.00US$8.762
Mar ’25US$13.73
US$21.00
+52.95%
4.76%US$22.00US$20.00US$11.942
Feb ’25US$14.77
US$21.00
+42.18%
4.76%US$22.00US$20.00US$13.442
US$16.5
Fair Value
39.1% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/05 18:03
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entrada Therapeutics, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Paul ChoiGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.